Vimarsana
Biggest News Aggregation in the World

Page 11 - Alacyclovir News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alacyclovir. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alacyclovir Today - Breaking & Trending Today

Merck's COVID Pill Doesn't Cut Death Rates in Many Vaxxed Adults - Vimarsana News

Merck's COVID Pill Doesn't Cut Death Rates in Many Vaxxed Adults

Merck's COVID antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in higher-risk vaccinated adults, detailed data from a large study showed.

Pfizer Says It Is Working to Improve Supply of COVID Drug Paxlovid in China - Vimarsana News

Pfizer Says It Is Working to Improve Supply of COVID Drug Paxlovid in China

Drugmaker Pfizer said on Tuesday it is working to improve supply of its COVID-19 antiviral drug Paxlovid in China in order to ensure adequate access to the drug as cases rise in the country.

US to Pay Pfizer Nearly $2 Billion for More Paxlovid Courses in 2023 - Vimarsana News

US to Pay Pfizer Nearly $2 Billion for More Paxlovid Courses in 2023

The US government agreed to pay Pfizer nearly $2 billion for an additional 3.7 million courses of its COVID-19 antiviral treatment Paxlovid, the company said on Tuesday.

COVID Drugs Dwindle; Canada Needle Exchange; and New CMS Rule - Vimarsana News

COVID Drugs Dwindle; Canada Needle Exchange; and New CMS Rule

The top 3 things you should know to start your day.

As COVID Treatments Dwindle, Are New Ones Waiting in the Wings? - Vimarsana News

As COVID Treatments Dwindle, Are New Ones Waiting in the Wings?

With the last monoclonal antibody treatment de-authorized, experts are focused on existing and new antivirals, new monoclonals, and convalescent plasma (again).